Who are Gabapentin Extended Release tablets's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Gabapentin/B-complex, Lyrica (pregabalin), Pregabalin capsule, stander treatment pregabalin, Pregabalin Dose Level 1, Pregabalin Dose Level 2.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gabapentin-extended-release-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Gabapentin Extended Release tablets — Competitive Intelligence Brief

Gabapentin Extended Release tablets (Gabapentin Extended Release tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticonvulsant / Analgesic. Area: Neurology / Pain Management.

phase 3 Anticonvulsant / Analgesic Alpha-2-delta subunit of voltage-gated calcium channels Neurology / Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Gabapentin Extended Release tablets (Gabapentin Extended Release tablets) — Depomed. Gabapentin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Gabapentin Extended Release tablets TARGET	Gabapentin Extended Release tablets	Depomed	phase 3	Anticonvulsant / Analgesic	Alpha-2-delta subunit of voltage-gated calcium channels
Gabapentin/B-complex	Gabapentin/B-complex	Merck KGaA, Darmstadt, Germany	marketed	Anticonvulsant/analgesic combination with vitamin supplementation	Alpha-2-delta subunit of voltage-gated calcium channels (gabapentin component)
Lyrica (pregabalin)	Lyrica (pregabalin)	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	marketed	Gabapentinoid; anticonvulsant; anxiolytic	Alpha-2-delta subunit of voltage-gated calcium channels
Pregabalin capsule	Pregabalin capsule	Guang'anmen Hospital of China Academy of Chinese Medical Sciences	marketed	Gabapentinoid; anticonvulsant; anxiolytic	Alpha-2-delta subunit of voltage-gated calcium channels
stander treatment pregabalin	stander treatment pregabalin	Hawler Medical University	marketed	Gabapentinoid; anticonvulsant; anxiolytic	Alpha-2-delta subunit of voltage-gated calcium channels
Pregabalin Dose Level 1	Pregabalin Dose Level 1	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	phase 3	Gabapentinoid; anticonvulsant; anxiolytic; analgesic	Alpha-2-delta subunit of voltage-gated calcium channels
Pregabalin Dose Level 2	Pregabalin Dose Level 2	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	phase 3	Gabapentinoid; anticonvulsant; anxiolytic; analgesic	Alpha-2-delta subunit of voltage-gated calcium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticonvulsant / Analgesic class)

Depomed · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Gabapentin Extended Release tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/gabapentin-extended-release-tablets. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab